Chat with us, powered by LiveChat

Discuss

Explore topical blogs discussing chemical safety assessment.

degradation and nitrosamine risk assessment webinar blog cover image

Did you miss our webinar on degradation chemistry and nitrosamine risk assessment? Here are 5 top takeaways!

If you couldn’t join us for our recent webinar, “Identifying the Formation of Nitrosamines via Degradation Pathways Using an In-Silico Approach,” we’ve got you covered! We explored how Zeneth, our cutting-edge software solution, can help you detect potential degradation issues early in the drug development workflow, specifically in the context of nitrosamine risk assessment. We

Did you miss our webinar on degradation chemistry and nitrosamine risk assessment? Here are 5 top takeaways! Read More »

How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits

How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits

Nitrosamines, a class of chemical compounds known for their potential carcinogenic properties, have become a significant concern for the pharmaceutical industry. In line with revised guidance from the European Medicines Agency (EMA), regulatory agencies require N-nitrosamines risk assessments to be performed on all marketed medical products investigating nitrosamine formation potential and their mutagenic and carcinogenic

How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits Read More »

Blog image 1

10 frequently asked questions about Derek Nexus, answered

For over four decades, at Lhasa Limited we have been developing scientific software solutions that enable scientists to make informed decisions on the safety of drugs, chemicals and cosmetics. Our journey advanced significantly with the creation of Derek Nexus, an in silico expert knowledge-based toxicity prediction tool. As regulatory landscapes evolved and the push for

10 frequently asked questions about Derek Nexus, answered Read More »

A new life in Leeds at Lhasa 4

Key insights from the Lhasa Limited & IPEC Europe Nitrites meeting

Explore key insights from the Lhasa Limited and IPEC Europe Nitrites meeting, where attendees discussed advancing nitrosamine understanding.   “The meeting provided an opportunity to share our common difficulties and discuss solutions to establish robust and accurate methods for analysing nitrites in excipients.” We recently welcomed members of the Lhasa Nitrites data sharing consortium and

Key insights from the Lhasa Limited & IPEC Europe Nitrites meeting Read More »

Supporting the safe use of CDB in skincare products using Derek Nexus

Supporting the safe use of CBD in skincare products using Derek Nexus

Cannabidiol (CBD) is gaining prominence as a sought-after ingredient in skincare and beauty formulations, thanks to its notable anti-inflammatory, antioxidant and anti-bacterial properties. Derived directly from the hemp plant, this compound is increasingly being used as an ingredient in skincare products, particularly for the management of various skin conditions like eczema, dermatitis and psoriasis. Despite

Supporting the safe use of CBD in skincare products using Derek Nexus Read More »

Untitled 1080 x 864 px 1

Fostering cross-cultural connections through art

Diversity serves as a catalyst for innovation at Lhasa. We believe in cultivating a workplace culture that encourages collaboration, and empowers every individual to express themselves fully. Art has the power to promote a culture of creativity, self-expression and community playing an integral role in enriching the fabric of our environment. Serving as a powerful

Fostering cross-cultural connections through art Read More »

zeneth blog 1

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways Read More »

Untitled design 12

Mitigating the risks of NDSRI’s through data sharing

At Lhasa, we believe in the transformative power of knowledge sharing as the driving force to support the global challenge of nitrosamine risk assessment. Through data sharing and industry collaboration, we empower members to further understand the risks associated with their potential nitrosamine impurities. The Vitic Complex Nitrosamines initiative, launched in 2021 in response to

Mitigating the risks of NDSRI’s through data sharing Read More »